Table 1.

Autosomal Recessive Congenital Ichthyosis: Genes and Distinguishing Clinical Features

Gene 1% of All ARCI 2Distinguishing Clinical FeaturesOtherSelected OMIM Links / References
ABCA12 3%-12%
  • Accounts for >93% of HI; biallelic complete loss-of-function variants were assoc w/most severe HI.
  • CIE or LI presented in those w/variants w/partial function; often assoc w/severe erythroderma & PPK.
  • Albeit extremely rare, a mosaic form of CIE due to postzygotic somatic mosaicism has been observed.
  • ~4% of distinct variants are large deletions/duplications. 3
  • Missense variants in the region coding for the 1st nuclear binding fold were assoc w/LI & predicted to interfere w/specific functions of this protein domain.
OMIM 601277;
OMIM 242500;
Sakai et al [2009], van Leersum et al [2020]
ALOX12B 9%-21%
  • >75% of affected persons w/ALOX12B variants were born w/collodion membrane & later had mild-to-moderate CIE w/fine scaling & erythema.
  • Persons w/self-improving collodion ichthyosis
  • ~2% of distinct variants are large deletions/duplications. 3
  • The variant p.Tyr521Cys accounts for 22% of disease alleles.
OMIM 242100;
Hotz et al [2021]
ALOXE3 3%-10%
  • >33% of affected persons w/ALOXE3 variants were born w/collodion membrane & later had mild-to-moderate CIE w/fine scaling & erythema.
  • Intermediate phenotypes
  • Persons w/self-improving collodion ichthyosis
  • More common in Austria
  • ~10% of distinct variants are large deletions/duplications. 3
  • The variant p.Pro630Leu accounts for 40% of disease alleles & p.Arg234Ter accounts for 21%.
OMIM 606545;
Harting et al [2008], Hotz et al [2021]
CASP14 RareNo collodion membrane at birth, generalized fine, whitish scales, & no erythema OMIM 617320
CERS3 <1%-3%
  • Collodion membrane at birth, erythema & fine scales on face & trunk, larger, gray-brown scales on lower limbs, & hyperlinear palms/soles
  • A distinct feature is keratotic lichenification w/prematurely aged appearance of skin.
  • More common in Iran (5.6% of variants)
  • 1 multigene deletion reported incl CERS3 assoc w/syndromic ichthyosis.
  • See also footnote 4.
OMIM 615023
CYP4F22 3%-10%
  • Typically, erythroderma at birth but w/o collodion membrane & later in life present w/LI w/larger, white-gray scales & hyperlinear palms/soles
  • Persons w/self-improving collodion ichthyosis
  • ~3% of distinct variants are large deletions/duplications. 3
  • Less common in northern Europeans
OMIM 604777;
Scott et al [2013], Bučková et al [2016], Diociaiuti et al [2016], Noguera-Morel et al [2016]
LIPN <1%Childhood onset w/generalized fine, white scaling & minimal erythema
  • 5% of variants in Middle Eastern populations
  • To date, no large deletions/duplications have been reported. 3
OMIM 613943
NIPAL4 5%-9%
  • <30% of persons w/NIPAL4 variants have collodion membrane at birth.
  • Congenital ichthyosis w/coarse, gray-white scales, mild-to-moderate erythroderma, & sparing of face
  • Yellowish PPK & hypohidrosis
  • Specific electron microscopic (EM) abnormalities (classified as ARCI EM type 3) w/abnormal lamellar bodies & elongated perinuclear membranes in granular layer
  • More common in Scandinavia (12.5%)
  • Higher prevalence in Sweden, Denmark, & Norway, where NIPAL4-related ARCI accounts for ~90% of ARCI w/o collodion membrane presentation in those w/o TGM1 variants.
  • The variant p.Asn176Asp is a mutation hot spot, observed in 87% of disease alleles & 70% of persons tested.
  • To date, no large deletions/duplications have been reported. 3
OMIM 612281;
Dahlqvist et al [2007], Scott et al [2013], Bučková et al [2016], Ballin et al [2019]
PNPLA1 ≤5%
  • Typically, collodion membrane at birth & then transition to CIE phenotype w/scalp involvement & hyperlinear palms/soles
  • Mild disease w/generalized fine exfoliation & hyperkeratotic plaques over knees resembling progressive symmetric erythrokeratoderma
  • Ectropion, eclabium, & alopecia are lacking.
  • More common in Iran (15% of variants)
  • Higher prevalence in northern Africa, Spain, & Iran, likely due to founder variants
  • To date, no large deletions/duplications have been reported. 3
OMIM 615024;
Vahidnezhad et al [2017], Zimmer et al [2017]
SDR9C7 1%CIE & intermediate phenotypes w/PPK & frequent fungal infections of skin & nails.
  • More common in Austria (6% of variants)
  • To date, no large deletions/duplications have been reported. 3
OMIM 617574
SLC27A4 Rare; 4%-5% in Scandinavia & northern Europe
  • IPS: polyhydramnios & premature birth
  • Severe perinatal presentation w/respiratory asphyxia & thick, vernix caseosa-like scale or cobblestone-like hyperkeratosis on scalp, forehead, & trunk
  • Skin findings resolve over several weeks, transitioning to mild generalized follicular hyperkeratosis
  • Mainly in persons from Scandinavia & northern Europe
  • The variant c.504C>A (p.Cys168Ter) is a founder variant in persons of Scandinavian ancestry.
  • A deletion of exon 3 has been reported. 3
OMIM 608649;
Sobol et al [2011], Lwin et al [2016]
SULT2B1 <1%Collodion membrane at birth in most affected persons; later, LI-like phenotype w/milder scaling in large skin foldsReported in few consanguineous families from North Africa, Middle East, & South Asia Heinz et al [2017]
TGM1 24%-34%
  • ~70%-90% of persons w/LI phenotype have TGM1 variants.
  • TGM1 variants also reported in many persons w/much milder non-erythrodermic phenotypes.
  • Persons w/"bathing suit ichthyosis"
  • Persons w/self-improving collodion ichthyosis
  • More common in Scandinavia & Galicia
  • The variant c.877-2A>G is a Norwegian/German founder variant & is common in Norway, Finland, & North America.
  • The variants c.2278C>T (p.Arg760Ter) & c.1223_1227delACACA are founder variants in Galician population of Spain.
  • <1% of variants are large deletions/duplications. 3
OMIM 242300;
Shevchenko et al [2000], Raghunath et al [2003], Mazereeuw-Hautier et al [2009], Hackett et al [2010], Rodríguez-Pazos et al [2011], Fachal et al [2014]
Unknown 57%-17%

ARCI = autosomal recessive congenital ichthyosis; CIE = congenital ichthyosiform erythroderma; HI = harlequin ichthyosis; IPS = ichthyosis-prematurity syndrome; LI = lamellar ichthyosis; PPK = palmoplantar keratoderma

1.

Genes are listed alphabetically.

2.
3.

Does not represent the overall percentage of deletions/duplications among probands/families; data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

4.

Large contiguous deletions reported including CERS3 and ADAMTS1

5.

Based on several studies using multigene testing, 7%-17% of individuals with congenital ichthyosis do not have pathogenic variants in any of the known genes [Israeli et al 2013, Pigg et al 2016, Youssefian et al 2019, Seidl-Philipp et al 2020, Simpson et al 2020, Sun et al 2022]. Pathogenic variants have not been identified in any of the following situations: (1) one or more variants were identified in one of the known ichthyosis genes but are of uncertain clinical significance [Youssefian et al 2019]; (2) linkage of congenital ichthyosis has been suggested to two other loci on chromosome 19 [Fischer et al 2000, Virolainen et al 2000]; (3) homozygosity mapping in two consanguineous families identified a region on chromosome 12 (ARCI7) [Mizrachi-Koren et al 2005]; and (4) linkage to a locus on 15q26.3 ‒ possibly identical to the location of CERS3 ‒ has been suggested in an aboriginal family from Taiwan [Wu & Lee 2011].

From: Autosomal Recessive Congenital Ichthyosis

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.